- Home
- STG vs QNCX Comparison
STG vs QNCX Comparison
Compare STG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- QNCX
- Stock Information
- Founded
- STG 2003
- QNCX 2012
- Country
- STG China
- QNCX United States
- Employees
- STG N/A
- QNCX N/A
- Industry
- STG Other Consumer Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STG Real Estate
- QNCX Health Care
- Exchange
- STG Nasdaq
- QNCX Nasdaq
- Market Cap
- STG 73.4M
- QNCX 47.7M
- IPO Year
- STG 2018
- QNCX 2019
- Fundamental
- Price
- STG $8.92
- QNCX $2.00
- Analyst Decision
- STG
- QNCX Strong Buy
- Analyst Count
- STG 0
- QNCX 5
- Target Price
- STG N/A
- QNCX $8.00
- AVG Volume (30 Days)
- STG 17.3K
- QNCX 374.6K
- Earning Date
- STG 08-15-2025
- QNCX 08-12-2025
- Dividend Yield
- STG N/A
- QNCX N/A
- EPS Growth
- STG N/A
- QNCX N/A
- EPS
- STG 3.09
- QNCX N/A
- Revenue
- STG $269,356,990.00
- QNCX N/A
- Revenue This Year
- STG N/A
- QNCX N/A
- Revenue Next Year
- STG N/A
- QNCX N/A
- P/E Ratio
- STG $2.42
- QNCX N/A
- Revenue Growth
- STG N/A
- QNCX N/A
- 52 Week Low
- STG $4.25
- QNCX $0.51
- 52 Week High
- STG $11.06
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- STG 80.31
- QNCX 70.90
- Support Level
- STG $5.51
- QNCX $1.55
- Resistance Level
- STG $5.88
- QNCX $1.71
- Average True Range (ATR)
- STG 0.56
- QNCX 0.15
- MACD
- STG 0.28
- QNCX 0.02
- Stochastic Oscillator
- STG 92.75
- QNCX 89.09
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.